Blackstone Closes Hologic Buyout, Delisting Company with $76 Cash Per Share
Summary
Blackstone has finalized its buyout of Hologic, which has now been delisted from Nasdaq. The transaction involved a payment of $76 cash per share, with an additional potential $3 CVR per share contingent on 2026–27 Breast Health milestones. This significant M&A closure, not previously detailed in the recent timeline, adds a substantial asset to Blackstone's private equity portfolio, impacting its assets under management and future performance. The company also highlighted a five-year revenue compound annual growth rate of 14.9% and a long-term annual EPS growth rate of 16%, reinforcing its growth trajectory. Investors should monitor the integration of Hologic and the achievement of the CVR-related milestones.
At the time of this announcement, BX was trading at $112.67 on NYSE in the Finance sector, with a market capitalization of approximately $137.8B. The 52-week trading range was $101.73 to $190.09. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.